STING1 and neoplasm: Results from a phase I trial assessed a range of intratumoral ADU-S100 injection doses (NCT02675439) and showed that, as a single agent, this STING agonist therapy was well-tolerated, displayed evidence of systemic immune activation in the peripheral blood, and reduced or maintained size of the injected lesion in 94% of patients; however, significant changes within the TME immune infiltrate were not observed at two weeks post-treatment and overall tumor burden response rates were limited (144).